AYX 1

Drug Profile

AYX 1

Alternative Names: AYX-1

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator Adynxx
  • Class Analgesics; Oligonucleotides
  • Mechanism of Action Early growth response protein 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Pain
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pain; Postoperative pain

Most Recent Events

  • 01 Feb 2017 Adynxx initiates a phase II trial for Postoperative pain (Prevention) in USA (Intrathecal) (NCT02807428)
  • 17 Jun 2016 Adynxx plans a phase II trial for Postoperative pain (Prevention) in USA (Intrathecal) (NCT02807428)
  • 11 Aug 2015 Efficacy and adverse events data from a phase IIb study for Postoperative pain released by Adynxx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top